<DOC>
	<DOCNO>NCT00003945</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It yet know chemotherapy regimen effective cervical cancer . PURPOSE : Randomized phase III trial compare effectiveness three different chemotherapy regimen treat patient stage IVB , recurrent , persistent cervical cancer .</brief_summary>
	<brief_title>Comparison Three Chemotherapy Regimens Treating Patients With Stage IVB , Recurrent , Persistent Cervical Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare response rate survival patient stage IVB , recurrent , persistent carcinoma cervix treat cisplatin v cisplatin plus topotecan v methotrexate , vinblastine , doxorubicin , cisplatin ( MVAC ) . ( Arm III ( MVAC ) close accrual effective 07/23/2001 . ) - Compare toxic effect regimens patient population . - Compare health-related quality life patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord GOG performance status . Patients randomize one three treatment arm . ( Arm III close accrual effective 07/23/2001 . ) - Arm I : Patients receive cisplatin IV every 21 day . - Arm II : Patients receive topotecan IV 30 minute day 1-3 cisplatin IV ( begin topotecan infusion ) day 1 . Courses repeat every 21 day . - Arm III : Patients receive methotrexate IV day 1 , 15 , 22 , vinblastine IV day 2 , 15 , 22 , doxorubicin IV cisplatin IV day 2 . Courses repeat every 28 day . ( Arm III close accrual effective 07/23/2001 . ) Treatment arm continue maximum 6 course absence disease progression unacceptable toxicity . ( Arm III close accrual effective 07/23/2001 . ) Quality life assess randomization , course 2 , course 5 ( arm I II ) , course 4 ( arm III ) , 9 month . ( Arm III close accrual effective 07/23/2001 . ) Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 400 patient ( 133 per treatment arm ) accrue study within 2 year . ( Arm III close accrual effective 07/23/2001 . )</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage IVB , recurrent , persistent carcinoma cervix amenable curative treatment surgery and/or radiotherapy Eligible subtypes : Squamous cell carcinoma Adenosquamous carcinoma Adenocarcinoma Measurable disease physical examination , radiography , CT scan , MRI Measurable disease CT scan/MRI without biopsy confirmation allow lesion least 3 cm well define No craniospinal metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : GOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 time normal SGOT great 3 time normal Alkaline phosphatase great 3 time normal Renal : Creatinine great 1.5 mg/dL No bilateral hydronephrosis alleviate ureteral stent percutaneous drainage Other : Not pregnant nursing Fertile patient must use effective contraception No clinically significant infection No prior invasive malignancy within past 5 year except nonmelanoma skin cancer Body surface area great 2.0 m^2 PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 6 week since prior chemoradiotherapy recover No prior chemotherapy except use concurrently radiotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics See Chemotherapy At least 3 week since prior radiotherapy recover Surgery : Recovered prior surgery Other : No prior anticancer treatment would preclude study therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2004</verification_date>
	<keyword>recurrent cervical cancer</keyword>
	<keyword>stage IVB cervical cancer</keyword>
	<keyword>cervical squamous cell carcinoma</keyword>
	<keyword>cervical adenocarcinoma</keyword>
	<keyword>cervical adenosquamous cell carcinoma</keyword>
</DOC>